340B · Oncology and Specialty Access · Reimbursement Strategy
Fifteen years running it. Now I help you run yours.
Walters Rx Strategy is an independent health-system pharmacy advisory practice. I work with health systems, cancer centers, specialty pharmacies, and manufacturers on 340B compliance, patient access and reimbursement, specialty pharmacy access, and formulary and P&T strategy.
Services
Six practice areas, all of them operational. Each one starts from the same place: what is the exposure, what is it costing, and what are the three things worth doing first.
Program reviews, HRSA audit readiness, and contract pharmacy oversight for covered entities and grantees. You get findings tied to the compliance exposure and the revenue each gap costs you, plus a prioritized fix list your team can execute without me.
Patient assistance, copay, and foundation navigation, plus benefits investigation and prior authorization workflow design for oncology and specialty therapies. The measure that matters is days from referral to first dose, and how many patients fall out of the process before they get there.
Limited-distribution and payer network access, referral-to-fill improvement, and 340B-enabled contract pharmacy design. Where capture is leaking we find it. Where the network is closed we map what it would take to open it.
Formulary process design, P&T committee strategy, and evidence and dossier review for health-system pharmacy leaders. Built around what a P&T committee actually asks and what it needs in front of it before a drug moves.
Provider-side reimbursement and coverage education, oncology pathway and protocol review, and peer-level scientific exchange support for oncology pharmacy and infusion teams. Non-promotional, clinically grounded, and written for the audience that actually sits on the committee.
Interim director coverage, turnaround work, and executive advisory for a pharmacy in transition. Diversion incident, USP 800 inspection finding, DSCSA gap, or an oncology service line losing money: defined workstreams, defined exit criteria, from day one.
Who I work with
Every engagement is under a written scope. I do not publish client names or logos, and I do not use client work as marketing material.
Pharmacy, oncology, and finance leaders carrying 340B exposure, a large drug-spend portfolio, and a service line that has to perform. Usual entry point is a program review or a standing advisory retainer.
Infusion and oncology pharmacy teams where the binding constraint is time-to-therapy, prior authorization throughput, and the gap between regimen cost and what actually gets reimbursed.
Medical affairs, field medical, and reimbursement teams who need an accurate read on how health-system pharmacy evaluates, buys, and dispenses. Advisory and educational work only, non-promotional by design.
Health-system and independent specialty pharmacies working on accreditation, payer and limited-distribution network access, and referral-to-fill performance.
Hub, copay, and access-technology partners who need provider-side validation: what the workflow looks like inside a health system, and where a program helps versus where it adds friction.
What is different
Most pharmacy consulting ends in a sixty-page deck. This ends with three things to do Monday and a named owner for each one.
Fifteen years of health-system pharmacy leadership across acute care, a cancer center, infusion, and emergency department pharmacy. When we talk, you get what I would actually do and, just as often, what I would skip.
Short, plain-language findings with a prioritized fix list and an owner against each item. Your team should be able to run it without translation, and without me in the room.
No junior associates ghostwriting the report. No layered teams. No partner-on-paper, associate-in-practice routine. The person you talk to is the person doing the work.
About
Founder, Walters Rx Strategy
Walters Rx Strategy is built for leaders who need outcomes, not slide decks: 340B compliance and optimization, oncology and specialty pharmacy access, patient access and reimbursement strategy, and formulary and P&T guidance. You get a colleague in the room who has actually run the thing.
Apexus Advanced 340B Certified | MBA
I support Salix Compass, a nonprofit medication navigation service. We share the goal of helping patients get access to their medications and better understand the process of getting there. Learn more about their work at Weaver Crest™.
Insights
Short, non-promotional pieces on how health-system pharmacy actually makes decisions about access, evidence, and cost.
Formulary
The P&T packet is only part of it. Here is the sequence a new oncology agent moves through inside a health system, and the questions that decide whether it gets on formulary.
ReadAccess
Most delay is not payer review time. It sits in benefits investigation, incomplete referrals, and the handoffs between clinic, pharmacy, and hub. Where the days really go.
Read340B
340B savings are an institutional resource, not an automatic patient discount. How covered entities connect program savings to what a patient pays at the counter.
ReadThe first 30-minute call is on me. Tell me what you are working on. If I can help I will tell you how. If I cannot, I will tell you that too, and point you to someone who can.